43 results about "Pre targeting" patented technology

A mutant bispecific antibody that includes (a) a human hinge constant region from IgG having one or more amino acid mutations in the CH2 domain, (b) two scFvs; and (c) two Fvs has been constructed. This type of antibody displays enhanced clearance, which has been found to be particularly useful in the context of pre-targeting methods.

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

An assay method and kit is disclosed for detecting the presence of at least one predesignated, target antibody to a mycobacterium in a sample selected from one or more patient bodily fluids. The method comprises the following steps: (a) contacting the sample of one or more patient bodily fluids with at least one mycobacterium antigen on a lateral-flow assay membrane to bind to the target antibody in the sample; (b) previously, simultaneously or subsequently to step (a), binding the at least one mycobacterium antigen with a conjugated label producing a detectable signal; and (c) detecting the signal whereby the presence of the target antibody is determined in the sample by the intensity or presence of the signal. The method can further comprise the step of evaluating immunization status of the patient from whom the sample came by comparing the signal or lack thereof with immunizations previously received by the patient and in comparison to a known standard control. In a preferred embodiment, the mycobacterium antigen specifically binds to Mycobacterium tuberculosis specific antibodies. Preferably, the immunoassay of the present invention comprises a lateral-flow assay comprising a membrane, a conjugated label pad, and at least one mycobacterium antigen bound to the membrane. In a preferred embodiment, the at least one mycobacterium antigen is selected from the group consisting of 38 kDa and 16 kDa antigens.

The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the [3+2] cycloaddition, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural / biological targeting constructs (biotin / streptavidin). Size considerations and limitations associated with their endogenous nature severely limit the number of applications. The present invention describes how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct under physiological conditions, by way of a small or undetectable bond, can overcome these limitations.

F-18 radiolabeled peptides are prepared by reacting a peptide comprising a hydroxylamine, a thiosemicarbazide, a hydrazine or a free amine group with 4-[18F]Fluorobenzaledyde. Specific, non-limiting examples of F-18 radiolabeled peptides are described herein. The labeled peptides are useful, for example, in clinical positron emission tomography.

Described is a pretargeting method, and related kits, for targeted medical imaging and / or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has one or more axial substituents.

Described is a pretargeting method, and related kits, for targeted medical imaging and / or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other a cyclooctene or cyclooctyne.

The invention discloses a transverse dynamic control method for an intelligent car in the driving process based on driver characteristics. The transverse dynamic control method comprises the followingsteps that step 1, a two-degree-of-freedom car dynamics model is established as a reference model; step 2, a driver model reflecting the operating characteristics of a driver is established; step 3,a pre-targeted link is established; step 4, a closed-loop control system is established according to the reference model, the driver model and the pre-targeted link; step 5, a zero-order holder is used for discretizing the established closed-loop control system; step 6, a least square identification function is established; and step 7, the loss function for minimizing the position of the car is used as a target, the pre-targeted time is determined according to the delay time and the inertia time, the pre-targeted distance is determined through the preview time, and then the delay time and theinertia time are calculated iteratively, so that the purpose of dynamically determining all parameters is achieved. According to the transverse dynamic control method for the intelligent car in the driving process based on the driver characteristics, the consistency of the models during path following is ensured, and meanwhile, the riding comfort is improved.

An optical proximity correction method is disclosed, comprising establishing an optical proximity correction (OPC) model, and performing an OPC correction step to correct segments of a layout pattern. The OPC correction comprises the step of defining an edge of the layout pattern neighboring a hot-spot location on a mask to locate a target point and a dissection point. The step of locating the target point and the dissection point includes setting a plurality of pre-target points and pre-dissection points, and electing a target point and a dissection point for correcting the segments of the layout pattern from the pre-target points and pre-dissection points according to image quality of the pre-target points and pre-dissection points.

Described is a pretargeting method, and related kits, for targeted medical imaging and / or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has one or more axial substituents.

The invention belongs to the field of pharmaceutical preparations, and provides a pharmaceutical albumin nanoparticle, a preparation method and application of the nanoparticle to tumor targeting therapy. The nanoparticle is made from two types of proteins, namely avidin and albumin, encapsulating slightly-soluble antitumor drugs. The electrostatic interaction exists between avidin and albumin, and avidin in the nanoparticle can be combined with biotin. Avidin can target the nanoparticle encapsulating the drugs on a biotin enrichment part. Before the application of the nanoparticle, a biotinylated antibody is used for pre-targeting on a tumor part, and can improve the distribution of a nanoparticle preparation in the tumor part. The biotinylated antibody and the nanoparticle preparation are combined for therapy, thereby playing better antitumor effect than the effect played by the combination of a monoclonal antibody and an albumin nanoparticle without avidin.

A method and an ultrasound medical apparatus for confirming a focal point of a high-intensity focused ultrasound are disclosed. A method of confirming a focal point, for pre-targeting a location of a high-intensity ultrasound by synchronizing the high-intensity ultrasound and an imaging ultrasound and using a reflected signal of the synchronized imaging ultrasound and high-intensity ultrasound from a focal point to which the ultrasounds are transmitted, and an ultrasound medical apparatus for implementing the method are provided.

Described is a method, and a combination of agents for used therein, by which an agent administered to a subject can be rapidly cleared from circulation. This is achieved by providing an Administration Agent (e.g. a probe for pretargeting) with a reactive group and providing a Clearing Agent with another reactive group, said reactive groups forming a bio-orthogonally reactive pair. Preferably, the reactive pair comprises a cyclooctene or cyclooctyn as one reactant, and a diene as the other reactant. The method and combination can be used for the removal of any bindable molecule from circulation, such as an excess of a pre-targeting probe in the course of a pre-targeting method, a targeting or imaging agent delivered, or the removal of any biomolecule already present in circulation.

The invention relates to a pre-processing production system for deep-processing of automobile glass; the pre-processing production system comprises a sheet-taking table, a cutting machine, a sheet-breaking and air-bearing table, an edge grinding machine, a suction arm, a transition conveyor, a sheet washing machine, a power blower, a cleaning, testing, overturning and discharging conveyor, a corner conveyor, a pre-targeting machine, a silk printer, a silk-printing, testing, overturning and discharging conveyor, a drying machine, an air-cooler and a discharging machine; and the edge grinding machine comprises a wheel-grinding shaft, a rocker arm, a hand wheel, locking screws, an upright column, a table top and a grinding wheel for grinding edges. The pre-processing production system for deep-processing of the automobile glass has the following beneficial effects: manual equipment and automatic equipment and combined, so that the pipelining working of the pre-processing for deep-processing of the automobile glass is realized; the production system is simple and stable in processing quality of glass; the internal glass and the external glass of coaches and minibuses are processed on the production system, so that the production staff is reduced, the labor intensity is reduced, the production field is saved, the production efficiency is improved and the operating cost of enterprises is reduced effectively.

Described is a pretargeting method, and related kits, for targeted medical imaging and / or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds.

The invention discloses an image processing method and a camera. The method comprises the steps of using a preset image recognition method for carrying out image recognition on a source image in an image set, and obtaining a target source image according to a recognition result, wherein the target source image is a source image including preset target elements in the image set; taking the target source image as an input of a trained image recognition model, and obtaining a recognition result of the preset target element in the target source image; and marking the image type on the target source image according to the identification result, and performing highlighting identification on the preset target element in the target source image according to the identification result, the image type marking being used for indicating whether the image comprises the pre-target element or not. According to the method, the image is accurately identified through two times of image identification, and the image is labeled and classified, so that the labeling processing of the image has the advantages of high precision and high speed.

Disclosed herein, the invention pertains to methods and compositions that find use in radiosensitization of tumors and tumor samples based on the ability of a tumor sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is an optional pre-targeting moiety; M is an optional macromolecular carrier; and T is a radiosensitization agent for delivery to a target, including for example a therapeutic compound.

The invention discloses a ground terminal pointing error calibration system and method for a spatial chaotic laser communication system. The system comprises a ground laser emitting end, a collimatingand pre-targeting device, a photodetector, and an angular reflective mirror device disposed on the selected satellite, wherein the laser emitted from the ground laser transmitting end is transmittedto the selected satellite through the collimating and pre-targeting device; the angular reflective mirror device on the satellite reflects the laser reaching the satellite back to the ground; the reflected light returned to the ground is received by the photodetector and then transmitted to a data processing module; the data processing module calculates the pointing error and adjusts the parameterof the ground laser emitting end according to the pointing error, so as to realize calibration of the pointing error. The method and the system in the invention utilize an existing satellite terminalfor calibration of a ground transmitting base station, the system is simple in structure and low in cost, and is of great significance for testing and calibration of the ground base station.

Disclosed herein, the invention pertains to methods and compositions that find use in treatment, diagnosis, prognosis and characterization of disease and disease samples based on the ability of a disease sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is a pre-targeting moiety; M is a macromolecular carrier, C is a detectable moiety; and T is a compound for delivery to a target, including for example a therapeutic compound.

The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the Staudinger ligation, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural / biological targeting constructs (i.e. biotin / streptavidin). Size considerations and limitations associated with their endogenous nature severely limit the number of applications. The present invention describes how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct under physiological conditions, by way of a small or undetectable bond, can overcome these limitations.

An optical proximity correction method is disclosed, comprising establishing an optical proximity correction (OPC) model, and performing an OPC correction step to correct segments of a layout pattern. The OPC correction comprises the step of defining an edge of the layout pattern neighboring a hot-spot location on a mask to locate a target point and a dissection point. The step of locating the target point and the dissection point includes setting a plurality of pre-target points and pre-dissection points, and electing a target point and a dissection point for correcting the segments of the layout pattern from the pre-target points and pre-dissection points according to image quality of the pre-target points and pre-dissection points.

The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present invention achieve good tumor to non-tumor ratios of the therapeutic agents, and are effective for cancer therapy.